Truist Securities Reiterates Buy on PROCEPT BioRobotics, Lowers Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a Buy rating on PROCEPT BioRobotics (NASDAQ:PRCT) but has lowered the price target from $79 to $74.
August 02, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a Buy rating on PROCEPT BioRobotics but lowered the price target from $79 to $74. This indicates continued confidence in the company's prospects despite a slight reduction in expected valuation.
The reiteration of the Buy rating suggests that the analyst still sees strong potential in PROCEPT BioRobotics. However, the lowered price target indicates a slight adjustment in expected performance, which could lead to a moderate positive impact on the stock price as the Buy rating is maintained.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100